Click one of the video selections to view.
RPB researchers are working to improve the management and early detection of diabetic retinopathy and diabetic macular edema.
Click here to watch RPB's recent online educational event, "RPB Lunch & Learn: Eye on Diabetic Retinopathy," a free 1-hour session featuring RPB-supported researchers giving an overview of DR disease pathology and treatment options, as well as providing insight into new research directions.
An estimated 18 million American children and adults have diabetes. Within 10 years of diagnosis, 75 percent will have some degree of diabetic retinopathy. Diabetic retinopathy is caused by high blood sugar, which damages tiny blood vessels of the retina. In response, the body grows fragile new blood vessels (neovascularization) within the retina.
A person with diabetic retinopathy might notice symptoms only after damage is done. A doctor is usually able to detect retinal changes much sooner and can help prevent vision loss. Therefore, regular dilated eye exams are extremely important.
Diabetic retinopathy is the leading cause of new cases of blindness among people aged 20-74, but most vision loss due to diabetic retinopathy is preventable with early detection and intervention.
Symptoms of diabetic retinopathy may include blurred vision, changes in central vision, floating spots, and even sudden vision loss. The first two symptoms are caused by swelling (edema) of the macula, the part of the retina that gives us sharp central vision.
RPB launches awards in data science and Diabetic Eye Disease.
RPB grantees provide expert advice on DR as part of the "Lunch & Learn" series.
Dr. Semenza is being recognized for his discoveries related to how cells respond to low oxygen levels, which have implications for the treatment of cancer, eye diseases and more.
A study from an RPB-supported researcher at Northwestern University School of Medicine could speed up the diagnosis of retinal diseases.
At the ARVO Inaugural Press Conference, three RPB-funded scientists pushing the boundaries of imaging, early detection, regeneration.
RPB-supported commentary on approaches to using the anti-VEGF therapy.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
| General Info | Grants | News & Resources |
Research to Prevent Blindness
360 Lexington Avenue, 22nd Floor
New York, NY 10017
(212) 752-4333
Copyright © 2023 Research to Prevent Blindness. All Rights Reserved.
